...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer Management and Research >Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors
【24h】

Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors

机译：458例卵巢肿瘤患者四种血清肿瘤标志物的临床分析：HE4，CA125，CA19-9和CEA联合应用对卵巢肿瘤的诊断价值

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To investigate the diagnostic values of human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA) for ovarian tumors. Methods: The participants were divided into three groups: 386 healthy women (control group), 262 patients with benign ovarian tumors (the benign group), and 196 patients with malignant pelvic tumors (the malignant group). The serum levels of HE4, CA125, CA19-9, and CEA were analyzed by electrochemiluminescent immunoassay. Results: It showed that serum levels of HE4, CA125, CA19-9, and CEA of patients with -malignant ovarian tumors were significantly higher than those in the control group and benign group ( P 0.05). Conclusion: The combination of three or four tumor markers did not improve the diagnostic efficacy when compared with the combination of HE4 and CA125.
机译：目的：探讨人附睾蛋白4（HE4），碳水化合物抗原125（CA125），碳水化合物抗原19-9（CA19-9）和癌胚抗原（CEA）对卵巢肿瘤的诊断价值。方法：参与者分为三组：386名健康女性（对照组），262例卵巢良性肿瘤患者（良性组）和196例恶性盆腔肿瘤患者（恶性组）。通过电化学发光免疫分析法分析HE4，CA125，CA19-9和CEA的血清水平。结果：表明卵巢恶性肿瘤患者的血清HE4，CA125，CA19-9和CEA水平显着高于对照组和良性组（P 0.05）。结论：与HE4和CA125联合使用相比，三种或四种肿瘤标志物联合使用不能提高诊断效率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号